Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
细胞周期
细胞骨架 抗体-药物偶联物
/
ADC毒素
微管 连接子-载荷偶联物
/ Monomethyl Auristatin F

Monomethyl Auristatin F {[allProObj[0].p_purity_real_show]}

货号：A309085 同义名： MMAF

MMAF can inhibit tubulin polymerization used in ADCs, with lower cytotoxic activity than MMAE.

Monomethyl Auristatin F 化学结构 CAS号：745017-94-1
Monomethyl Auristatin F 化学结构
CAS号：745017-94-1
Monomethyl Auristatin F 3D分子结构
CAS号：745017-94-1
Monomethyl Auristatin F 化学结构 CAS号：745017-94-1
Monomethyl Auristatin F 3D分子结构 CAS号：745017-94-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Monomethyl Auristatin F 纯度/质量文件 产品仅供科研

货号：A309085 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Monomethyl Auristatin F 生物活性

描述 MMAF is a potent auristatin-derived antineoplastic agent, working by inhibition of tubulin polymerization[1]. Different from its analogue MMAE, it has attenuated cytotoxicity due its charged C-terminal phenylalanine. MMAF exhibited cytotoxicity in Karpas 299, H3396, 786-O and Caki-1 cells with IC50 values of 119nM, 105nM, 257nM and 200nM after 96-hour treatment[2]. For the high toxicity of MMAF, it is usually used as the payload of ADCs (antibody-drug conjugates), such as combination with antibody-drug conjugates such as vorsetuzumab mafodotin or SGN-CD19A[3]. Through the link to specific antibody, the selectivity and potency of MMAF could be proved. For example, the ADC cAC10-L4-MMAF4 (anti-CD30) showed cytotoxicity to Karpas 299 cells with IC50 value of 0.065 nM (compared with 119nM, MMAF alone). Intravenous injection with cAC10-L4-MMAF4 at dose of 2mg/kg almost suppressed the median tumor growth in SCID mice xenograft Karpas 299 human ALCL tumors. And the survival was significantly prolonged when the mice were dosed of 8mg/kg cAC10-L4-MMAF4[2].
作用机制 MMAF is an auristatin derivate which can inhibi tubulin polymerization and destabilize microtubule structure.[1]

Monomethyl Auristatin F 动物研究

Dose Rat: 5 mg/kg[4] (i.v.); 10 mg/kg[4] (p.o.)
Administration i.v., p.o.
Pharmacokinetics
Animal Rats[4]
Dose 5 mg/kg (i.v.)
10 mg/kg (p.o.)
Administration i.v.
p.o.
AUClast 65661.30 min·ng/ml (i.v.)
CL 77.33 ml/min/kg (i.v.)
Cmax 8276.76 ng/ml (i.v.)
Vss 1057.13 ml/kg (i.v.)

Monomethyl Auristatin F 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02064387 Multiple Myeloma Phase 1 Active, not recruiting September 28, 2020 United States, Massachusetts ... 展开 >> GSK Investigational Site Boston, Massachusetts, United States, 02215 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48109 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New York GSK Investigational Site New York, New York, United States, 10065 United States, North Carolina GSK Investigational Site Chapel Hill, North Carolina, United States, 27599-7600 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, Texas GSK Investigational Site Dallas, Texas, United States, 75390-8565 United States, Washington GSK Investigational Site Seattle, Washington, United States, 98109 Canada, British Columbia GSK Investigational Site Vancouver, British Columbia, Canada, V5Z 1M9 Canada, Ontario GSK Investigational Site Toronto, Ontario, Canada, M5G 2M9 United Kingdom GSK Investigational Site London, United Kingdom, NW1 2BU GSK Investigational Site Manchester, United Kingdom, M20 4BX 收起 <<
NCT01672775 Carcinoma, Renal Cell ... 展开 >> Renal Cell Carcinoma of Papillary Histology Renal Cell Carcinoma With Clear Cell Histology Renal Cell Carcinoma With Non-Clear Cell Histology 收起 << Phase 1 Completed - United States, Michigan ... 展开 >> Site US00005 University of Michigan Medical Center Ann Arbor, Michigan, United States, 48109 Site US00003 Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New York Site US00004 Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Site US00002 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Washington Site US00001 Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Canada, Alberta Site CA00006 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia Site CA00008 British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Site CA00009 London Health Sciences Centre London, Ontario, Canada, N6A 4L6 Canada, Quebec Site CA00007 Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 收起 <<

Monomethyl Auristatin F 参考文献

[1]Chen H, Lin Z, et al. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017 Aug 1;22(8). pii: E1281.

[2]Doronina SO, Mendelsohn BA, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

[3]Donaghy H, et al. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016 May-Jun;8(4):659-71.

[4]Park MH, Lee BI, et al. Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Molecules. 2019 Jul 29;24(15). pii: E2754.

Monomethyl Auristatin F 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.37mL

0.27mL

0.14mL

6.83mL

1.37mL

0.68mL

13.66mL

2.73mL

1.37mL

Monomethyl Auristatin F 技术信息

CAS号745017-94-1
分子式C39H65N5O8
分子量 731.962
别名 MMAF
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature
溶解度

DMSO: 135 mg/mL(184.44 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: MMAF | 745017-94-1 | Monomethylauristatin F | Microtubule/Tubulin | Tubulin Inhibitor | Cell Cycle/DNA Damage | Antibody-drug Conjugate/ADC Related | Cytoskeleton | Microtubule/Tubulin | ADC Cytotoxin | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Monomethyl Auristatin F 纯度/质量文件 | Monomethyl Auristatin F 生物活性 | Monomethyl Auristatin F 动物研究 | Monomethyl Auristatin F 临床数据 | Monomethyl Auristatin F 参考文献 | Monomethyl Auristatin F 实验方案 | Monomethyl Auristatin F 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z